Homoarginine (hArg) and asymmetric dimethylarginine (ADMA) in short stature children without and with growth hormone deficiency: hArg and ADMA are involved differently in growth in the childhood

Amino Acids

Volumn 47, Issue 9, 2015, Pages 1875-1883

  Langen, Jennifer ^a   Kayacelebi, Arslan Arinc ^b   Beckmann, Bibiana ^b   Weigt Usinger, Katharina ^a   Carmann, Christina ^a   Hörster, Irina ^a   Lilienthal, Eggert ^a   Richter Unruh, Annette ^c   Tsikas, Dimitrios ^b   Lücke, Thomas ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

ADMA; Arginine; Children; Growth hormone; Homoarginine; IGF 1; Short stature

Indexed keywords

EDETIC ACID; GROWTH HORMONE; HOMOARGININE; N(G),N(G) DIMETHYLARGININE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; THYROTROPIN; ARGININE; HUMAN GROWTH HORMONE; N,N-DIMETHYLARGININE;

ADOLESCENT; AMINO ACID BLOOD LEVEL; ARTICLE; BODY MASS; CHILD; CONTROLLED STUDY; FEMALE; GAS CHROMATOGRAPHY; GROWTH HORMONE DEFICIENCY; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; SEX DIFFERENCE; SHORT STATURE; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; VALIDITY; ADULT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DEFICIENCY; GROWTH DISORDERS; METABOLISM; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; ARGININE; CHILD; FEMALE; GROWTH DISORDERS; HOMOARGININE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE;

EID: 84940722910     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-015-2028-8     Document Type: Article

References (57)

1. Atzler D, Rosenberg M, Andersso M, Choe CU, Lutz M, Zugck C, Böger RH, Frey N, Schwedhelm E (2013) Homoarginine - an independent marker of mortality in heart failure. Int J Cardiol 168:4907-4909
2. Baars J, Van den Broeck J, le Cessie S (1998) Body mass index in growth hormone deficient children before and during growth hormone treatment. Horm Res 49:39-45
3. Binder G (2014) Kleinwuchs und Therapie. Monatsschrift Kinderheilkunde 162:299-308
4. Brooks ER, Langmann CB, Wang S, Price HE, Hodges AL, Darling L, Yang AZ, Smith FA (2009) Methylated arginine derivates in children and adolescents with chronic kidney disease. Pediatr Nephrol 24:129-134
5. Bulow B, Hagmar L, Mikoczy Z, Nordström CH, Erfurth EM (1997) Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrin 46:75-81
6. Capaldo B, Guardasole V, Pardo F, Matarazzo M, Di Rella F, Numis F, Merola B, Longobardi S, Sacca L (2001) Abnormal vascular reactivity in growth hormone deficiency. Circulation 103(4):520-524
7. Chobanyan-Jürgens K, Fuchs A-J, Tsikas D, Kanzelmeyer N, Das AM, Illsinger S, Vaske B, Jordan J, Lücke T (2012) Increased asymmetric dimethylarginine (ADMA) dimethylaminohydrolase (DDAH) activity in childhood hypercholesterinemia type II. Amino Acids 43(2):805-811
8. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM (1998) Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91(10):3527-3561
9. Colao A, Di Somma C, Filippella M, Rota F, Piconello R, Orio F, Vitale G, Lombardi G (2004) Insulin-like growth factor-1 deficiency determines increased intima-media thickness at common carotid arteries in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf) 61(3):360-366
10. Colao A, Di Somma C, Spiezia S, Rota F, Pivonello R, Savastano S, Lombardi G (2006) The natural history of partial growth hormone deficiency in adults: a prospective study on the cardiovascular risk and atherosclerosis. J Clin Endocrinol Metab 91(6):2191-2200
11. Cooke JP (2006) Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of angiogenesis. Eur J Clin Pharmacol 62:115-121
12. Cooke JP, Dzau VJ (1997) Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 48:489-509
13. Davids M, Ndika JD, Salomons GS, Blom HJ, Teerlink T (2012) Promiscuous activity of arginine:glycine amidinotransferase is responsible for the synthesis of the novel cardiovascular risk factor homoarginine. FEBS Lett 586:3653-3657
14. Davis PH, Dawson JD, Riley WA, Lauer RM (2001) Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation 104:2815-2819
15. Dawson JD, Sonka M, Blecha MB, Lin W, Davis PH (2009) Risk factors associated with aortic and carotid intima-media thickness in adolescents and young adults: the Muscatine Offspring Study. J Am Coll Cardiol 53(24):2273-2279
16. De Marco S, Marcovecchio ML, Caniglia D, De Leonibus C, Chiarelli F, Mohn A (2014) Circulating asymmetric dimethylarginine and lipid profile in pre-pubertal children with growth hormone deficiency: effect of 12-month growth hormone replacement therapy. Growth Horm IGF Res 5:216-220
17. Drechsler C, Meinitzer A, Pilz S, Krane V, Tomaschitz A, Ritz E, März W, Wanner C (2011) Homoarginine, heart failure, and sudden cardiac death in haemodialysis patients. Eur J Heart Fail 13:852-859
18. Foster C, Burton A, Scholl J, Scott ML, Gunter V, McCormick K (2014) Lipid patterns in treated growth hormone deficient children vs. short stature controls. J Pediatr Endocrinol Metab 27:909-914
19. Goonasekera CDA, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ (1997) Nitric oxide synthase inhibition and hypertension in children and adolescents. J Hypertens 15:901-909
20. Hecker M, Walsh DT, Vane JR (1991) On the substrate specificity of nitric oxide synthase. FEBS Lett 294:221-224
21. Jehlicka P, Stozicky F, Mayer OJR, Varvarovska J, Racek J, Trefil L, Siala K (2009) Asymmetric dimethylarginine and the effect of folat substitution in children with familial hypercholesterolemia and diabetes mellitus type I. Physiol Res 58:179-184
22. Kanzelmeyer N, Tsikas D, Chobanyan-Jürgens K, Beckmann B, Vaske B, Illsinger S, Das AM, Lücke T (2011) Asymmetric dimethylarginine in children with homocystinuria or phenylketonuria. Amino Acids 42(5):1765-1772
23. Kayacelebi AA, Pham VV, Willers J, Hahn A, Stichtenoth DO, Jordan J, Tsikas D (2014a) Plasma homoarginine (hArg) and asymmetric dimethylarginine (ADMA) in patients with rheumatoid arthritis: is homoarginine a cardiovascular corrective in rheumatoid arthritis, an anti-ADMA? Int J Cardiol 176(3):1129-1131
24. Kayacelebi AA, Beckmann B, Gutzki FM, Jordan J, Tsikas D (2014b) GC-MS and GC- MS/MS measurement of the cardiovascular risk factor homoarginine in biological samples. Amino Acids 46:2205-2217
25. Kayacelebi AA, Knöfel AK, Beckmann B, Hanff E, Warnecke G, Tsikas D (2015a) Measurement of unlabeled and stable isotope-labeled homoarginine, arginine and their metabolites in biological samples by GC-MS and GC-MS/MS. Amino Acids. doi: 10.1007/s00726-015-1984-3
26. Kayacelebi AA, Langen J, Weigt-Usinger K, Chobanyan-Jürgens K et al (2015b) Biosynthesis of homoarginine (hArg) and asymmetric dimethylarginine (ADMA) from acutely and chronically administered free l-arginine in humans. Amino Acids. doi: 10.1007/s00726-015-2012-3
27. Khadilkar V, Ekbote V, Kajale N, Khadilkar A, Chiplonkar S, Kinare A (2014) Effect of one-year growth hormone therapy on body composition and cardio-metabolic risk in Indian children with growth hormone deficiency. Endocr Res 39(2):73-78
28. Khalil AA, Tsikas D, Akolekar R, Jordan J, Nicolaides KH (2013) Asymmetric dimethylarginine, arginine and homoarginine at 11-13 weeks' gestation and preeclampsia: a case-control study. J Hum Hypertens 27:38-43
29. Kielstein A, Tsikas D, Galloway GP, Mendelson JE (2007) Asymmetric dimethylarginine (ADMA) - a modulator of nociception in opiate tolerance and addiction? Nitric Oxide 17:55-59
30. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, Rosén T, Lindstedt G, Lundberg PA, Bengtsson BA (1994) Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol (Oxf) 41:351-357
31. Leifke E, Kinzel M, Tsikas D, Gooren L, Frölich JC, Brabant G (2008) Effects of normalization of plasma testosterone evels in hypogonadal men on plasma levels and urinary excretion of asymmetric dimethylarginine (ADMA). Horm Metab Res 40:56-59
32. Leiper M, Vallance P (2006) The synthesis and metabolism of asymmetric dimethylarginine (ADMA). Eur J Clin Pharmacol 62:33-38
33. Li G, Del Rincon JP, Jahn LA, Wu Y, Gaylinn B, Thorner MO, Liu Z (2008) Growth hormone exerts acute vascular effects independent of systemic or muscle insulin-like growth factor I. J Clin Endocrinol Metab 93:1379-1385
34. Lombardi G, Di Somma C, Vuolo L, Guerra E, Scarano E, Colao A (2010) Role of IGF-I on PTH effects on bone. J Endocrinol Invest 33(7 Suppl):22-26
35. Lücke T, Tsikas D, Kanzelmeyer N, Vaske B, Das AM (2006) Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in citrullinemia. Metabolism 55:1599-1603
36. Lücke T, Kanzelmeyer N, Kemper MJ, Tsikas D, Das AM (2007) Developmental changes in the l-arginine/nitric oxide pathway from infancy to adulthood: plasma asymmetric dimethylarginine levels decrease with age. Clin Chem Lab Med 45:1525-1530
37. Lücke T, Kanzelmeyer N, Chobanyan K, Tsikas D, Franke D, Kemper MJ, Ehrich JHH, Das AM (2008) Elevated asymmetric dimethylarginine (ADMA) and inverse correlation between circulating ADMA and glomerular filtration rate in children with sporadic focal semental glomerulosclerosis (FSGS). Nephrol Dial Transplant 23:734-740
38. März W, Meinitzer A, Drechsler C, Pilz S, Krane V, Kleber ME, Fischer J, Winkelmann BR, Böhm BO, Ritz E, Wanner C (2010) Homoarginine, cardiovascular risk, and mortality. Circulation 122:967-975
39. Moali C, Boucher JL, Sari MA, Stuehr DJ, Mansuy D (1998) Substrate specificity of NO synthases: detailed comparison of l-arginine, homo-l-arginine, their N omega- hydroxy derivatives, and N omega-hydroxynor-l-arginine. Biochemistry 37:10453-10460
40. Önder A, Aycan Z, Koca C, Ergin M, Çetinkaya S, Aʇladioʇlu SY, Peltek Kendirci HN, Baş VN (2014) Evaluation of asymmetric dimethylarginine (ADMA) levels in children with growth hormone deficiency. J Clin Res Pediatr Endocrinol 6(1):22-27
41. Pilz S, Tomaschitz A, Meinitzer A, Drechsler C, Ritz E, Krane V, Wanner C, Böhm BO, März W (2011a) Low serum homoarginine is a novel risk factor for fatal strokes in patients undergoing coronary angiography. Stroke 42:1132-1134
42. Pilz S, Meinitzer A, Tomaschitz A, Drechsler C, Ritz E, Krane V, Wanner C, Böhm BO, März W (2011b) Low homoarginine concentration is a novel risk factor for heart disease. Heart 97:1222-1227
43. Pilz S, Teerlink T, Scheffer PG, Meinitzer A, Rutters F, Tomaschitz A, Drechsler C, Kienreich K, Nijpels G, Stehouwer CD, März W, Dekker JM (2014) Homoarginine and mortality in an older population: the Hoorn study. Eur J Clin Invest 44:200-208
44. Pilz S, Meinitzer A, Gaksch M, Grübler M, Verheyen N, Drechsler C, Hartaigh BÓ, Lang F, Alesutan I, Voelkl J, März W, Tomaschitz A (2015a) Homoarginine in the renal and cardiovascular systems. Amino Acids. doi: 10.1007/s00726-015-1993-2
45. Pilz S, Putz-Bankuti C, Meinitzer A, März W, Kienreich K, Stojakovic T, Pieber TR, Stauber RE (2015b) Association of homoarginine and methylarginines with liver dysfunction and mortality in chronic liver disease. Amino Acids. doi: 10.1007/s00726-015-2000-7
46. Rosen T, Bengtsson BA (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336(8710):285-288
47. Rosenbaum M, Gernter JM, Leiber RL (1989) Effects of systemic growth hormone (GH) administration on regional adipose tissue distribution and metabolism in GH- deficient children. J Clin Endocrinol Metab 69:1274-1281
48. Scalera F, Borlak J, Beckmann B, Martens-Lobenhoffer J, Thum T, Täger M, Bode-Böger SM (2004) Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl l-arginine accelerates endothelial cell senescence. Arterioscler Thromb Vasc Biol 24:1816-1822
49. Setola E, Monti LD, Lanzi R, Lucotti P, Losa M, Gatti E, Galluccio E, Oldani M, Fermo I, Giovannelli M, Bosi E, Piatti PM (2008) Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency. Metabolism 57:1685-1690
50. Thum T, Fleissner F, Klink I, Tsikas D, Jakob M, Bauersachs J, Stichtenoth DO (2007) Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-I. J Clin Endocrinol Metab 92:4172-4179
51. Tomaschitz A, Verheyen N, Gaksch M, Meinitzer A, Pieske B, Kraigher-Krainer E, Colantonio C, März W, Schmidt A, Belyavskiy E, Rus-Machan J, van Ballegooijen AJ, Stiegler C, Amrein K, Ritz E, Fahrleitner-Pammer A, Pilz S (2015) Homoarginine in patients with primary hyperparathyroidism. Am J Med Sci 349:306-311
52. Tsikas D (2009) De novo synthesis of trideuteromethyl esters of amino acids for use in GC-MS and GC-tandem MS exemplified for ADMA in human plasma and urine: standardization, validation, comparison and proof of evidence for their aptitude as internal standards. J Chromatogr B Analyt Technol Biomed Life Sci 877(23):2308-2320
53. Tsikas D, Kayacelebi AA (2014) Do homoarginine and asymmetric dimethylarginine act antagonistically in the cardiovascular system? Circ J 78(8):2094-2095
54. Tsikas D, Schubert B, Grutzki FM, Sandmann J, Frölich JC (2003) Quantitative determination of circulating and urinary asymmetric dimethylarginine (ADMA) in humans by gas chromatography-tandem mass spectometry as methyl ester tri(N- pentrafluoropropionyl) derivate. J Chromatogr B Analyt Technol Biomed Life Sci 798:87-99
55. Valtonen P, Laitinen T, Lyyra-Laitinen T, Raitakari OT, Juonala M, Viikari JS, Heiskanen N, Vanninen E, Punnonen K, Heinonen S (2008) Serum l-homoarginine concentration is elevated during normal pregnancy and is related to flow-mediated vasodilatation. Circ J 72:1879-1884
56. van Ballegooijen AJ, Reinders I, Visser M, Dekker JM, Nijpels G, Stehouwer CD, Pilz S, Brouwer IA (2013) Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: the Hoorn study. J Clin Endocrinol Metab 98:E638-E645
57. Wu G, Bazer FW, Davis TA, Kim SW, Li P, Marc Rhoads J, Carey Satterfield M, Smith SB, Spencer TE, Yin Y (2009) Arginine metabolism and nutrition in growth, health and disease. Amino Acids 37:153-168